Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Provided By GlobeNewswire
Last update: Aug 5, 2025
Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25
Read more at globenewswire.com
